RGNT Stock Catalyst: Regentis Biomaterials Ltd. Accelerates Commercial Launch with European Surgeon Training for GelrinC

Jun 8, 2026 · 7:14am ET

Training program is part of preparations for the commercial launch of GelrinC in knee cartilage repair.

Max move

+469.4%

High of day $6.89

Sparker timei

7:14am ET

RGNT · Jun 8, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Regentis Biomaterials Ltd. (NYSE: RGNT) announced the commencement of a European surgeon training program for its GelrinC product, aimed at knee cartilage repair. This initiative is a key step in the company's preparations for the commercial launch of GelrinC.

The training program will equip surgeons with the necessary skills and knowledge to effectively use GelrinC in clinical settings. Regentis Biomaterials Ltd. has a free float of 2,371,812 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time RGNT sparks.

Download Sniper App →

Catch the next RGNT-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

RGNT Stock Catalyst: Regentis Biomaterials Ltd. Accelerates Commercial Launch with European Surgeon Training for GelrinC

RGNT · Jun 8, 2026

RGNT · Jun 8, 2026

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.